Cervarix denied FDA priority review

Share this article:

GlaxoSmithKline said yesterday that the FDA has denied the drugmaker its request for a priority review of its experimental cancer vaccine Cervarix.

Cervarix now faces a standard 10-month review, instead of the six-month review usually granted under a priority review. 

A priority review is often only granted to new treatments when no drugs are available for a particular illness. However, Cervarix rival, Merck’s Gardasil, is already on the market. 

GSK expects a Cervarix action date by the FDA in January 2008.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.